COMBINATION OF MITOXANTRONE HYDROCHLORIDE LIPOSOME WITH CYTARABINE IN PEDIATRIC PATIENTS WITH NEWLY DIAGNOSED AML: PHARMACOKINETICS, SAFETY AND EFFICACY

EHA Library, Wenyu Yang, 419910

IMPROVED CARE-PATHWAY CAN INCREASE THE OVERALL SURVIVAL AMONG ACUTE MYELOID LEUKAEMIA PATIENTS: A POPULATION-BASES STUDY USING DOUBLY ROBUST CAUSAL INFERENCE METHODS.

EHA Library, Kueshivi Midodji ATSOU, 419911

VALIDATION OF OPTICAL GENOME MAPPING AS A POTENTIAL STANDARD OF CARE CYTOGENOMIC METHODOLOGY IN CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Joanna Kamaso, 419912

PLCG2 Δ20-22 EXON-SKIPPED VARIANTS IN PRIMARY CLL

EHA Library, Jialei Qi, 419913

CODING AND REGULATORY REGIONS AFFECTED BY 17P AND 11Q DELETIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Romana Nesnadná, 419914

GENE POLYMORPHISM AND PRIMARY MULTIPLE METACHRONIC TUMORS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AND MULTIPLE MYELOMA

EHA Library, Elena Nazarova, 419915

CYTOGENOMIC RESPONSE EVOLUTION IN TREATED CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS USING OPTICAL GENOME MAPPING AND NEXT-GENERATION SEQUENCING

EHA Library, Rocío García-Serra, 419916

CHARACTERIZATION OF CD38 EXPRESSION IN T-CELL PROLYMPHOCYTIC LEUKEMIA (T-PLL) PATIENTS: A SINGLE-CENTER EXPERIENCE OF 20 CASES

EHA Library, Giulia Calabretto, 419917

PREDICTING CLINICAL RESPONSE OF NON-HODGKIN LYMPHOMA WITH AN EX VIVO TUMOR MICROENVIRONMENT MODEL

EHA Library, Shazia Nakhoda, 419918

DISTINCT PATTERNS OF IN VIVO CLASS SWITCH RECOMBINATION EVENTS IN DIFFERENT IMMUNOGENETIC SUBGROUPS OF CLL: IMPLICATIONS FOR DISEASE ONTOGENY

EHA Library, Electra Sofou, 419919

OUTCOMES OF EPIC: A NON-INTERVENTIONAL, OBSERVATIONAL STUDY OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA TREATED WITH FIRST-LINE ACALABRUTINIB VIA THE UK EARLY ACCESS PROGRAMME; INTERIM ANALYSES.

EHA Library, Nicolas Martinez-Calle, 419920

PATIENT-REPORTED OUTCOME (PRO)–BASED RECURRENT SYMPTOMATIC DETERIORATION PREDICTS DISEASE PROGRESSION: RESULTS FROM THE ALPINE TRIAL

EHA Library, Jennifer R. Brown, 419921

CROSS-STUDY COMPARISON OF IBRUTINIB PLUS VENETOCLAX (I+V) VS VENETOCLAX PLUS OBINUTUZUMAB (V+G) IN SUBJECTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH COMORBIDITIES

EHA Library, Francisco Javier Lopez Jimenez, 419922

RISK OF HYPERTENSION IN PATIENTS WITH CLL/SLL WHO PARTICIPATED IN ALPINE: A POST HOC ANALYSIS

EHA Library, William B. White, 419923

POSTINFUSION RESOURCE USE AND COST OF LISOCABTAGENE MARALEUCEL BY RESPONSE STATUS AND PRIOR LINES OF THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA FROM TRANSCEND CLL 004

EHA Library, November McGarvey, 419924

IMPACT OF IGHV SUBSETS ON THE ROBUSTNESS OF DIFFERENT RISK SCORES TO PREDICT CLL PROGRESSION

EHA Library, Miguel Argüello de Tomás, 419925

UPDATED RESULTS OF COMBINATION TREATMENT WITH IBRUTINIB AND VENETOCLAX IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AND COMPLEX KARYOTYPE: 4-YEAR FOLLOW-UP

EHA Library, Maria Kislova, 419926

RISK ADAPTED MANAGEMENT OF PATIENTS WITH EARLY-STAGE ASYMPTOMATIC CHRONIC LYMPHOCYTIC LEUKEMIA USING ACALABRUTINIB WITH OR WITHOUT OBINUTUZUMAB

EHA Library, Sameer Parikh, 419927

A PHASE II STUDY OF TIME-LIMITED TREATMENT WITH ACALABRUTINIB PLUS OBINUTUZUMAB IN PATIENTS WITH TREATMENT-NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Jan Burger, 419928

REAL-WORLD EFFECTIVENESS OF VENETOCLAX-RITUXIMAB IN BTKI-NAÏVE AND BTKI-EXPERIENCED RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS IN BELGIUM

EHA Library, Sylvia Snauwaert, 419930

REAL-WORLD EVIDENCE STUDY OF PATIENTS TREATED FOR RELAPSED/REFRACTORY CLL WITH VENETOCLAX AND RITUXIMAB FOR A FIXED DURATION : AVENIR, A FRENCH MULTICENTRIC RETROSPECTIVE COHORT STUDY

EHA Library, Laemmel Lucie, 419931

REAL-WORLD FIRST LINE CHRONIC LYMPHOCYTIC LEUKEMIA TREATMENT IN GERMANY IN THE ERA OF TARGETED AGENTS

EHA Library, Zuzana Dostalova, 419932

REAL-WORLD CLINICAL OUTCOMES OF FIRST-LINE IBRUTINIB DOSE REDUCTION VERSUS ACALABRUTINIB AMONG PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA

EHA Library, Mazyar Shadman, 419933

RISK OF NEW-ONSET HYPERTENSION IN NEWLY DIAGNOSED CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH BRUTON TYROSINE KINASE INHIBITORS: A REAL-WORLD STUDY USING THE SYMPHONY HEALTH SOLUTIONS DATABASE

EHA Library, William B. White, 419934

SAFETY AND EFFECTIVENESS OF CLL PATIENTS TREATED WITH VENETOCLAX IN COMBINATION WITH OBINUTUZUMAB OR RITUXIMAB UNDER REAL-WORLD CONDITIONS IN AUSTRIA, GERMANY, AND SWITZERLAND

EHA Library, Ingo Schwaner, 419935

PREDICTING PFS BENEFIT FROM CR RATES IN R/R CLL: A POOLED ANALYSIS OF RANDOMIZED CONTROLLED TRIALS (RCT)

EHA Library, Loïc Ysebaert, 419936

SAFETY AND EFFICACY OF IBRUTINIB IN INDIAN CLL PATIENTS WITH 17P DELETION.

EHA Library, Sujeet Kumar, 419937

PRELIMINARY SAFETY AND EFFICACY DATA FROM PATIENTS WITH RELAPSED OR REFRACTORY B-CELL MALIGNANCIES TREATED WITH ICP-248, A NOVEL BCL2 INHIBITOR.

EHA Library, Shuhua Yi, 419938

ACCELERATED CHRONIC LYMPHOCYTIC LEUKEMIA – THE CHARACTERISTICS AND RETROSPECTIVE ANALYSIS OF TREATMENT OUTCOMES IN POLISH HEMATOLOGY CENTERS

EHA Library, Bartosz Puła, 419939

INCIDENCE OF PNEUMONIA IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA TREATED WITH VENETOCLAX-BASED REGIMENS: A REAL-WORLD ANALYSIS OF PALG, THE POLISH ADULT LEUKEMIA GROUP

EHA Library, Elżbieta Kalicińska, 419940

DIVERSIFYING CLINICAL TRIAL ENROLLMENT: DEVELOPING A NOVEL METHOD OF CLINICAL TRIAL SITE SELECTION TO IMPROVE CLINICAL TRIAL DIVERSITY

EHA Library, Brittaney-Belle Gordon, 419941

REAL-WORLD OUTCOMES OF ORELABRUTINIB AS FIRST-LINE TREATMENT IN CLL/SLL: A MULTICENTER STUDY

EHA Library, Huayuan Zhu, 419942

ANALYSIS OF OUTCOMES OF YOUNGER (≤ 55 YEARS) COMPARED WITH OLDER (> 55 YEARS) PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL)

EHA Library, TALBI FAIZA, 419943

A SENSIBLE AND SPECIFIC AUTOMATED SYSTEM FOR THE DETECTION OF DIFFERENT BCR::ABL1 REARRANGEMENTS IN PHILADELPHIA-POSITIVE LEUKEMIAS AT DIAGNOSIS

EHA Library, Stefania Stella, 419944

SOMATIC MUTATIONS IN CHRONIC MYELOID LEUKEMIA PATIENTS AFTER TYROSINE KINASE INHIBITORS TREATMENT FAILURE AND IN OPTIMAL RESPONSE.

EHA Library, Elena Kuzmina, 419945

IMPACT OF MOLECULAR RESPONSE DEPTH AT DISCONTINUATION AS A PROGNOSTIC FACTOR OF SUSTAINED TREATMENT-FREE REMISSION IN CHRONIC MYELOID LEUKEMIA PATIENTS IN THE AST TRIAL.

EHA Library, Carolina Pavlovsky, 419946

COVID-19 IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA: FINAL RESULTS FROM THE GLOBAL OBSERVATIONAL ICMLF CANDID STUDY

EHA Library, Delphine Rea, 419947

TYROSINE KINASE INHIBITOR WITHDRAWAL SYNDROME AND PSYCHOLOGICAL ISSUES IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA AFTER THERAPY DISCONTINUATION

EHA Library, Mengyao Yuan, 419948

PATIENT REPORTED OUTCOMES IN ADULTS WITH TKI-RESISTANT CHRONIC MYELOID LEUKEMIA RECEIVING OLVEREMBATINIB-THERAPY

EHA Library, Lu Yu, 419949

TKI-FREE INTERVAL (TFI) FOR SAFE NAVIGATION OF PLANNED PREGNANCY IN NON-TFR ELIGIBLE FEMALE CML PATIENTS.

EHA Library, Sujeet Kumar, 419950

CLINICAL AND LABORATORY CHARACTERISTICS OF PATIENTS WITH RARE BCR::ABL1 FUSION TRANSCRIPTS

EHA Library, Yanbo Nie, 419951

ASCIMINIB (ASC) IS WELL TOLERATED IN PEDIATRIC PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP): INTERIM PHARMACOKINETICS AND SAFETY RESULTS FROM ASC4KIDS

EHA Library, Nobuko Hijiya, 419952

COMPARISON OF EARLY TREATMENT RESPONSE & SAFETY OF LOWER DOSE (70 MG/DAY) VERSUS STANDARD DOSE (100 MG/DAY) OF GENERIC DASATINIB IN CHRONIC PHASE CML: RANDOMIZED CONTROLLED STUDY FROM INDIA

EHA Library, Paras Satadeve, 419953

RESULTS OF THERAPY OF ASCIMINIB AND PONATINIB IN CHRONIC MYELOID LEUKEMIA PATIENTS WITH FAILURE TO MORE THAN 2 TYROSINE KINASE INHIBITORS AND / OR BCR::ABL1 T315I MUTATION

EHA Library, Ekaterina Chelysheva, 419954

DELINEATING THE PATHOGENIC POTENTIAL OF DEAD-BOX ATP-DEPENDENT RNA HELICASE 41 GENE (DDX41) GERMLINE MUTATIONS IN HEREDITARY MYELOID NEOPLASMS

EHA Library, Marwa Almosailleakh, 419955

IMPACT OF NICHE CELLS IN THE PROGRESSION OF MDS TO SECONDARY AML

EHA Library, Mireia Atance Pasarisas, 419956

UNVEILING EPIGENETIC DYNAMICS: OXFORD NANOPORE SEQUENCING REVEALS GENOME-WIDE DNA METHYLATION PATTERNS IN CD34+ CELLS OF HR-MDS PATIENTS UNDERGOING ORAL AZACITIDINE THERAPY

EHA Library, Sven De Pourcq, 419957

MONOCYTES FROM PATIENTS WITH MYELODYSPLASTIC SYNDROME INHIBIT NK CELL-MEDIATED ANTI-TUMOR FUNCTION THROUGH THE CD200/CD200R PATHWAY

EHA Library, Zhaoyun Liu, 419958

CHARACTERIZING GENE EXPRESSION CHANGES IN MYELODYSPLASTIC SYNDROME PATIENTS WITH MUTATIONS IN COHESIN SUBUNIT STAG2 AT BULK AND SINGLE CELL RESOLUTION

EHA Library, Shubhra Ashish Bhattacharya, 419959

DETECTION OF PATHWAY ACTIVITY IN CELLULAR PROCESSES

EHA Library, Priyansh Srivastava, 419960

PROTEASOME PROTEOLYTIC ACTIVITY AND OTHER MARKERS OF RED BLOOD CELL PHYSIOLOGY AS INDICATORS OF DISEASE RISK AND THERAPEUTIC INTERVENTION IN MYELODYSPLASTIC SYNDROMES

EHA Library, Pinelopi Vryttia, 419961

MOUSE PDX MODELS TO EXPLORE DUAL RESISTANCE OF PROGRESSING MDS/AML TO 5-AZACYTIDINE AND VENETOCLAX.

EHA Library, Tomas Stopka, 419962

VULNERABILITY OF CSNK1A1 MUTATIONS TO FERROPTOSIS IN DEL(5Q) MYELODYSPLASTIC SYNDROMES

EHA Library, Stephani Schmitz, 419963

ACCELERATED SENESCENCE OF BONE MARROW NUCLEATED ERYTHROCYTES IN MYELODYSPLASTIC SYNDROME

EHA Library, Mengyuan Liu, 419964

THE ROLE OF MDS-MSC DERIVED EXOSOMES IN REGULATION OF MDS CLONED CELL MALIGNANT PROLIFERATION THROUGH RN7SL1/RIG-I SIGNAL

EHA Library, JUAN GUO, 419965

GLOBAL ASSESSMENT OF THE MRNA DECAY DURING ERYTHROPOIESIS REVEALS ITS INVOLVEMENT IN NORMAL AND DEFECTIVE ERYTHROPOIESIS

EHA Library, Zubaidan Tuerdi, 419966

NOVEL THERAPEUTIC VULNERABILITIES IN DEL(5Q) MYELOID MALIGNANCIES

EHA Library, Sergio Martinez Høyer, 419967

COMPARATIVE ANALYSIS OF IMMUNE CELL DISTRIBUTION IN PERIPHERAL BLOOD AND BONE MARROW SAMPLES: CONTRASTING PATTERNS IN CONTROL SUBJECTS AND LOWER-RISK MYELODYSPLASTIC NEOPLASMS PATIENTS

EHA Library, Ioannis Kotsianidis, 419968

CIRCULAR RNA EXPRESSION IN MYELODYSPLASTIC SYNDROME HSPCS IS ASSOCIATED WITH THE EXPRESSION OF PROLIFERATION MARKERS AND RISK OF DISEASE PROGRESSION.

EHA Library, Eileen Wedge, 419969

MINIMAL RESIDUAL DISEASE IN CD34+ CELLS IN MYELODYSPLASTIC SYNDROME AFTER ALLOGENIC STEM CELL TRANSPLANTATION

EHA Library, Carolin Lindholm, 419970

GENOMIC EVOLUTION OF PATIENTS WITH MYELOID NEOPLASMS AND KNOWN ANTECEDENT CLONAL HEMATOPOIESIS

EHA Library, Kelly Chien, 419971

THE CLINICAL OUTCOME AND MOLECULAR SPECTRUM OF ASXL1 MUTATION IN MYELODYSPLASTIC SYNDROME

EHA Library, Juan Peng, 419972

CLINICAL EXPERIENCE WITH LUSPATERCEPT THERAPY IN LOW-RISK MYELODYSPLASTIC SYNDROMES WITH TRANSFUSION DEPENDENCY, POSITIVE EFFECT OF COMBINATION THERAPY WITH ERYTHROPOIETIN.

EHA Library, Anna Jonasova, 419973

EFFICACY AND PROGNOSTIC ASSESSMENT OF CHEMOTHERAPY-BRIDGED TRANSPLANTATION IN PEDIATRIC PATIENTS WITH ADVANCED MYELODYSPLASTIC SYNDROMESXINGCHEN

EHA Library, Xingchen Wang, 419974

UNDERSTANDING THE REAL-WORLD BURDEN OF LIVING WITH MYELODYSPLASTIC SYNDROME ACROSS THE EU5: DISCORDANCE BETWEEN PHYSICIAN AND PATIENT PERSPECTIVES

EHA Library, Katie Lewis, 419975

REAL WORLD OUTCOME OF THE FORMERLY KNOWN MDS-EB2 CATEGORY: ANALYSIS ACCORDING TO THE NEW 2022ICC/WHOCLASSIFICATIONS,IWG2023/ELN RESPONSE CRITERIA AND IPSS-M AND ELN PROGNOSTICS SYSTEMS.A GESMD STUDY

EHA Library, Sandra Castaño-Díez, 419976

OUTCOMES OF ORAL DECITABINE-CEDAZURIDINE USING A THREE- OR FIVE-DAY REGIMEN IN PATIENTS WITH MYELODYSPLASTIC OR OVERLAP SYNDROMES

EHA Library, Jonathan Hyak, 419977

IMPLEMENTATION OF OPTICAL GENOME MAPPING IN THE CYTOGENETICS DIAGNOSIS OF MYELODYSPLASTIC NEOPLASMS

EHA Library, Neus Torres Hernández, 419978

REFERRAL PATTERNS TO A SPECIALTY CLONAL HEMATOPOIESIS OF INDETERMINATE POTENTIAL (CHIP) CLINIC IN NEW YORK CITY

EHA Library, Sushruta Iruvanti, 419979

SERUM HYPOALBUMINEMIA IS AN INDEPENDENT PROGNOSTIC FACTOR IN CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML)

EHA Library, Rami S. Komrokji, 419980

AZACITIDINE COMBINED WITH LUSPATERCEPT IN ELDERLY PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROME: RESULTS OF AN OPEN-LABEL PROSPECTIVE MULTICENTER TRIAL IN CHINA

EHA Library, Hongju Yan, 419981

SPECTRUM AND CLINICAL IMPLICATIONS OF COHESIN MUTATIONS IN PATIENTS WITH HIGHER RISK MYELODYSPLASTIC SYNDROMES/NEOPLASMS (MDS) TREATED WITH HYPOMETHYLATING AGENTS (HMA)

EHA Library, Jessica M. Stempel, 419982

CLINICAL CHARACTERISTICS AND GENETIC LANDSCAPE OF A COHORT OF CHILDREN WITH MYELODYSPLASTIC NEOPLASMS FROM ARGENTINA

EHA Library, Maria Florencia Mininni, 419983

A PHASE I STUDY OF THE MYELOID CELL LEUKEMIA 1 (MCL1) INHIBITOR TAPOTOCLAX (AMG 176) IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES AFTER HYPOMETHYLATING AGENT FAILURE

EHA Library, Kelly Chien, 419984

EFFICACY/SAFETY OF LUSPATERCEPT FOR ANEMIA TREATMENT IN TRANSFUSION DEPENDENT (TD) LOWER-RISK (LR) MYELODYSPLASTIC SYNDROME WITH RING SIDEROBLASTS (MDS-RS): A PHASE 2 BRIDGING STUDY IN ASIAN PATIENTS

EHA Library, Zhijian Xiao, 419985

MODIFIED OGATA SCORE FOR THE DIAGNOSIS OF MYELOID DYSPLASIA IN A REAL-WORLD CLINICAL PRACTICE

EHA Library, Fiona O'Flynn, 419986

DISTINCT CLINICAL AND PROGNOSTIC FEATURES OF MYELODYSPLASTIC SYNDROME IN PATIENTS FROM THE MIDDLE EAST, NORTH AFRICA, AND BEYOND: A SYSTEMIC REVIEW

EHA Library, Amal Al-Haidose, 419987

BIOINFORMATICS ANALYSIS EXPLORES PATHOGENIC LINK BETWEEN AA AND MDS

EHA Library, Qinglin Hu, 419988

PERFORMANCE AND ACTIONABILITY OF GERMLINE GENETIC TESTING CRITERIA FOR PREDISPOSITION TO HEMATOLOGIC NEOPLASMS IN ADULTS

EHA Library, Sara Torres-Esquius, 419989

CLINICAL OUTCOMES OF PATIENTS WITH SETBP1 MUTATED MYELOID NEOPLASMS

EHA Library, Aref Al-Kali, 419990

STUDY ON THE CORRELATION BETWEEN BONE MARROW ADIPOCYTOKINES SUCH AS LEPTIN AND NAMPT AND MYELODYSPLASTIC NEOPLASMS

EHA Library, yuchun li, 419991

COMBINATION OF DECITABINE AND ETOPOSIDE IS HIGHLY EFFECTIVE IN TREATING P53-MUTATED MDS/AML

EHA Library, Jiexian Ma, 419992

CLINICAL IMPLICATIONS OF RAS PATHWAY MUTATIONS IN HIGHER RISK MYELODYSPLASTIC SYNDROMES/NEOPLASMS (MDS) TREATED WITH HYPOMETHYLATING AGENTS (HMA) - A MULTICENTER, RETROSPECTIVE ANALYSIS

EHA Library, Ted M. Getz, 419993

PROGNOSTIC SCORING SYSTEMS IPSS, IPSS-R AND IPSS-M HAD NO IDENTICAL PROGNOSTIC POWER DEPENDING ON TREATMENT IN MYELODYSPLASTIC SYNDROMES

EHA Library, Ghada Abichou, 419994

COMPARISON OF THE 2022 WORLD HEALTH ORGANIZATION CLASSIFICATION AND INTERNATIONAL CONSENSUS CLASSIFICATION IN MYELODYSPLASTIC SYNDROMES (MDS)

EHA Library, Yu-Sung Chang, 419995

LUSPATERCEPT UTILIZATION PATTERNS IN LOWER-RISK MYELODYSPLASTIC SYNDROME (LR-MDS): FINDINGS FROM A MULTINATIONAL MEDICAL RECORD REVIEW STUDY

EHA Library, María Díez Campelo, 419996

REAL-WORLD EXPERIENCE OF AZACITIDINE COMBINED WITH TISLELIZUMAB IN THE ELDERLY WITH HIGHER-RISK MYELODYSPLASTIC SYNDROME.

EHA Library, Chen Yang, 419997

PROSPECTIVE ASSESSMENT OF RESPONSE IN A PHASE II TRIAL OF VENETOCLAX AND AZACITIDINE IN THERAPY-RELATED MDS WITH INTERNATIONAL WORKING GROUP 2006 AND 2023 CRITERIA FOR MYELODYSPLASTIC SYNDROMES

EHA Library, Kelly Pugh, 419998

THE ABILITY OF BLOOD SERUM TO SUPPORT THE PROLIFERATION OF BONE MARROW DERIVED MESENCHYMAL STROMAL CELLS IS REDUCED IN APLASTIC ANEMIA

EHA Library, Alena Dorofeeva, 419999

EXPLORING THE ROLE OF INTESTINAL FLORA IN THE PATHOGENESIS OF APLASTIC ANEMIA BASED ON INTEGRATED METABOLOMICS AND 16S RRNA SEQUENCING

EHA Library, Siyuan Cui, 420000

MULTIPOTENT MESENCHYMAL STROMAL CELLS FROM THE BONE MARROW OF PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA ARE AFFECTED DIFFERENTLY THAN CELLS OF PATIENTS WITH APLASTIC ANEMIA WITH PNH-CLONE

EHA Library, Alena Dorofeeva, 420001

TRANSFUSION AVOIDANCE WITH EPYSQLI™ (SB12), A BIOSIMILAR TO REFERENCE ECULIZUMAB: A POST-HOC ANALYSIS FROM THE PIVOTAL PHASE III STUDY.

EHA Library, Jun Ho Jang, 420003

REAL-WORLD EXPERIENCE OF PEGCETACOPLAN TREATMENT IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) WITH UNSATISFACTORY RESPONSE TO PREVIOUS THERAPEUTIC APPROACHES

EHA Library, Juan Carlos Vallejo Llamas, 420004

PATIENT EXPERIENCE OF IPTACOPAN IN THREE CLINICAL TRIALS FOR PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

EHA Library, Carlos de Castro, 420005

CYCLOSPORINE PLUS AVATROMBOPAG VERSUS CYCLOSPORINE ALONE FOR FIRST-LINE TREATMENT OF ELDERLY PATIENTS WITH TRANSFUSION-DEPENDENT NON-SEVERE APLASTIC ANEMIA: A SINGLE CENTER, RETROSPECTIVE STUDY

EHA Library, Zhuxin Zhang, 420006

EXPOSURE-RESPONSE MODELING USING POPULATION PK/PD METHODS RELIABLY PREDICT POPULATION AND INDIVIDUAL RESPONSES OF COMPLEMENT MATURE FACTOR D, HEMOGLOBIN AND LDH IN PNH PATIENTS EXPOSED TO OMS906

EHA Library, William Pullman, 420007

DECREASED REGULATORY T CELLS IN CHILDREN WITH AUTOIMMUNE NEUTROPENIA

EHA Library, Konstantina Toutoudaki, 420008

EFFICACY OF ROMIPLOSTIM IN NEWLY DIAGNOSED APLASTIC ANAEMIA

EHA Library, MADHUPRIYA B, 420009

UPFRONT MATCHED UNRELATED DONOR HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SEVERE IDIOPATHIC APLASTIC ANEMIA AND REFRACTORY CYTOPENIA OF CHILDHOOD IN PEDIATRIC PATIENTS. A STUDY OF THE SPANISH PEDIATRIC GROUP FOR HEMATOPOIETIC CELL TRANSPLANTATION AND CE

EHA Library, Luz Uría Oficialdegui, 420010

THE SILENT ROLE OF COPPER: HEMATOLOGICAL CONSEQUENCES OF ITS DEFICIENCY.

EHA Library, Magdalena María Gonzalez, 420011